The estimated Net Worth of Harry Fisch is at least $2.16 Milion dollars as of 24 May 2024. Dr Fisch owns over 4,000 units of Veru Inc stock worth over $674,020 and over the last 7 years he sold VERU stock worth over $835,000. In addition, he makes $648,118 as Vice Chairman & Chief Corp. Officer at Veru Inc.
Dr has made over 31 trades of the Veru Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 4,000 units of VERU stock worth $5,000 on 24 May 2024.
The largest trade he's ever made was selling 100,000 units of Veru Inc stock on 16 June 2021 worth over $835,000. On average, Dr trades about 9,211 units every 58 days since 2017. As of 24 May 2024 he still owns at least 774,736 units of Veru Inc stock.
You can see the complete history of Dr Fisch stock trades at the bottom of the page.
Dr. Harry Fisch F.A.C.S., M.D. is the Vice Chairman & Chief Corp. Officer at Veru Inc.
As the Vice Chairman & Chief Corp. Officer of Veru Inc, the total compensation of Dr D at Veru Inc is $648,118. There are 3 executives at Veru Inc getting paid more, with Dr. Mitchell S. Steiner F.A.C.S, F.A.C.S., M.D. having the highest compensation of $1,426,295.
Dr D is 62, he's been the Vice Chairman & Chief Corp. Officer of Veru Inc since . There are 1 older and 9 younger executives at Veru Inc. The oldest executive at Veru Inc is Mario Eisenberger, 70, who is the Independent Director.
Harry's mailing address filed with the SEC is 2916 N. MIAMI AVENUE, SUITE 1000, MIAMI, FL, 33127.
Over the last 7 years, insiders at Veru Inc have traded over $5,672,221 worth of Veru Inc stock and bought 673,267 units worth $1,199,518 . The most active insiders traders include Mitchell Shuster Steiner, Harry Fisch a K Gary Barnette. On average, Veru Inc executives and independent directors trade stock every 33 days with the average trade being worth of $22,682. The most recent stock trade was executed by Harry Fisch on 24 May 2024, trading 4,000 units of VERU stock currently worth $5,000.
the female health company/veru healthcare is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. to realize this goal, veru healthcare has three divisions: pharmaceutical and devices, consumer health products, and public sector. for men, product and product candidates are in the areas of benign prostatic hyperplasia, male infertility, amelioration of side effects of hormonal prostate cancer therapies, prostate cancer, gout, and sexual dysfunction. women’s health has product candidates for female sexual health and advanced breast and ovarian cancers and markets fc2, a disposable contraceptive device, to ob gyn physicians and is the only female condom approved by fda that offers dual protection against sexually transmitted infections, including hiv/aids and the zika virus, and unintended pregnancy. since the female health company began distributing fc2 in 2007, the product has been shipped to 144 countries
Veru Inc executives and other stock owners filed with the SEC include: